1 June 2006 in European Journal of Endocrinology
TTThe European Thyroid Cancer Taskforce
The European Thyroid Cancer Taskforce
+1
Ive it requiring intense treatment and surveillance to cancers appointment of two thyroid cancer experts for each country. Twenty five countries answered positively and role of thyroglobulin (Tg), anti-Tg antibodies (AbTg) DOI: 10.1530/eje.1.02158 European Journal of Endocrinology (2006) 154 787–803 ISSN 0804-4643q 2006 Society of the European Journal of Endocrinologydetected by fortuitous neck ultrasonography (US) requiring less aggressive treatment and follow-up. Diagnostic and treatment tools have also improved in recent years (sensitive assays for serum thyroglobulin measurement, neck US, recombinant human thyrotro-pin (rhTSH)), thus allowing for less invasive and uncomfortable procedures for the patients. Altogether, these considerations dictate the need for applying the more effective, less invasive and less expensive pro-cedures able to guarantee the best management and the best quality of life for a disease that, albeit having an intrinsic low mortality, requires life-long follow-up care. and neck US; † protocols for early and long-term follow-up; † treatment of local and regional recurrences and of distant metastases. These issues were discussed in a meeting that took place in Athens on 24 May 2005. The experts were advised to base their statements on clinical and scientific evidence whenever available in the current literature. The first session of the meeting was devoted to presentations on the state of the art for each selected issue, followed by an extensive discussion. In the second session, the expertsEuropean consensus for the ma differentiated thyroid carcino
1 August 2010 in Clinical Oncology
4 May 2018 in Journal of Endocrinological Investigation
1 February 2022 in European Thyroid Journal
DHDaria Handkiewicz-Junak
+2
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
1 November 2005 in European Journal of Endocrinology
Objective: To determine, based on published literature and expert clinical experience, current indications for the post-surgical administration of a large radioiodine activity in patients with differentiated thyroid cancer. Design and methods: A literature review was performed and was then analyzed and discussed by a panel of experts from 13 European countries. Results: There is general agreement that patients with unifocal microcarcinomas = 1 cm in diameter and no node or distant metastases have a 1 cm and with suboptimal surgery (less than total thyroidectomy or no lymph node dissection), with age <16 years, or with unfavorable histology.
1 November 1999 in The Journal of Clinical Endocrinology & Metabolism
Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after thyroid hormone withdrawal. The objectives of this study were to compare the effect of administered recombinant human TSH with thyroid hormone withdrawal on the results of radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels. Two hundred and twenty-nine adult patients with differentiated thyroid cancer requiring radioiodine WBS were studied. Radioiodine WBS and serum Tg measurements were performed after administration of recombinant human TSH and again after thyroid hormone withdrawal in each patient. Radioiodine whole body scans were concordant between the recombinant TSH-stimulated and thyroid hormone withdrawal phases in 195 of 220 (89%) patients. Of the discordant scans, 8 (4%) had superior scans after recombinant human TSH administration, and 17 (8%) had superior scans after thyroid hormone withdrawal (P = 0.108). Based on a serum Tg level of 2 ng/mL or more, thyroid tissue or cancer was detected during thyroid hormone therapy in 22%, after recombinant human TSH stimulation in 52%, and after thyroid hormone withdrawal in 56% of patients with disease or tissue limited to the thyroid bed and in 80%, 100%, and 100% of patients, respectively, with metastatic disease. A combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation detected thyroid tissue or cancer in 93% of patients with disease or tissue limited to the thyroid bed and 100% of patients with metastatic disease. In conclusion, recombinant human TSH administration is a safe and effective means of stimulating radioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence.